Becton Dickinson and Co (BDX) Stake Decreased by Lincoln Capital LLC

Lincoln Capital LLC reduced its holdings in Becton Dickinson and Co (NYSE:BDX) by 0.4% during the first quarter, Holdings Channel reports. The institutional investor owned 19,288 shares of the medical instruments supplier’s stock after selling 86 shares during the quarter. Becton Dickinson and accounts for about 2.3% of Lincoln Capital LLC’s investment portfolio, making the stock its 16th largest holding. Lincoln Capital LLC’s holdings in Becton Dickinson and were worth $4,817,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the company. IMS Capital Management bought a new stake in shares of Becton Dickinson and during the third quarter valued at approximately $29,000. RPG Investment Advisory LLC bought a new stake in shares of Becton Dickinson and during the first quarter valued at approximately $32,000. Nalls Sherbakoff Group LLC purchased a new position in Becton Dickinson and during the fourth quarter valued at $34,000. Aspire Private Capital LLC purchased a new position in Becton Dickinson and during the fourth quarter valued at $39,000. Finally, Sontag Advisory LLC purchased a new position in Becton Dickinson and during the fourth quarter valued at $43,000. Hedge funds and other institutional investors own 84.87% of the company’s stock.

In other news, CEO Vincent A. Forlenza sold 3,123 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $796,458.69. Following the completion of the transaction, the chief executive officer now owns 215,372 shares in the company, valued at $54,926,321.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Ribo Alberto Mas sold 2,104 shares of the business’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $255.00, for a total value of $536,520.00. Following the completion of the transaction, the executive vice president now owns 19,074 shares of the company’s stock, valued at approximately $4,863,870. The disclosure for this sale can be found here. Insiders sold 29,684 shares of company stock valued at $7,518,574 in the last 90 days. Company insiders own 0.12% of the company’s stock.

Shares of NYSE:BDX opened at $240.02 on Wednesday. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.97 and a quick ratio of 0.62. The firm has a market cap of $66.24 billion, a price-to-earnings ratio of 21.80, a P/E/G ratio of 1.74 and a beta of 1.21.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.58 by $0.12. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The firm had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the previous year, the business earned $2.48 earnings per share. The company’s revenue was up 35.1% on a year-over-year basis. As a group, research analysts anticipate that Becton Dickinson and Co will post 12.08 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 8th were paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 1.28%. The ex-dividend date of this dividend was Thursday, March 7th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

A number of research analysts have issued reports on BDX shares. Morgan Stanley lowered their price objective on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 2nd. Raymond James lowered their price objective on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a research note on Tuesday, March 19th. Citigroup lowered their price objective on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating for the company in a research note on Wednesday, January 2nd. TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Finally, Zacks Investment Research cut Becton Dickinson and from a “hold” rating to a “sell” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and has an average rating of “Buy” and an average price target of $256.25.

TRADEMARK VIOLATION WARNING: This story was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2019/04/17/becton-dickinson-and-co-bdx-stake-decreased-by-lincoln-capital-llc.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: Stochastic Momentum Index (SMI)

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit